SCHEMBL294531

SCHEMBL294531

CC(C)COC(=O)C1CC1C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.41
HSP90AA1 P07900 1/20 0.40
HSP90AB1 P08238 1/20 0.40
POLB P06746 2/20 0.39
KDM4E B2RXH2 2/20 0.38
ALDH1A1 P00352 5/20 0.37
L3MBTL1 Q9Y468 3/20 0.37
RAB9A P51151 4/20 0.37
NPC1 O15118 3/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
MAPT P10636 2/20 0.35
MEN1 O00255 1/20 0.35
GAA P10253 1/20 0.35
NFKB1 P19838 1/20 0.35
MAPK1 P28482 1/20 0.35
NFKB2 Q00653 1/20 0.35
KMT2A Q03164 1/20 0.35
RELA Q04206 1/20 0.35
CAPN9 O14815 1/20 0.35
MCL1 Q07820 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1297720 0.89 TSHR (0.45) TSHRHSP90AA1HSP90AB1ALDH1A1RAB9A
SCHEMBL1196119 0.88 TSHR (0.41) TSHRHSP90AA1HSP90AB1POLBALDH1A1
SCHEMBL1196067 0.87 HSP90AA1 (0.36) TSHRHSP90AA1HSP90AB1POLBKDM4E
SCHEMBL27296220 0.87 TSHR (0.43) TSHRHSP90AA1HSP90AB1ALDH1A1RAB9A
SCHEMBL16865176 0.86 L3MBTL1 (0.38) HSP90AA1HSP90AB1POLBKDM4EALDH1A1
SCHEMBL1196371 0.86 HSP90AA1 (0.36) TSHRHSP90AA1HSP90AB1POLBKDM4E
SCHEMBL14214220 0.84 HSP90AA1 (0.35) TSHRHSP90AA1HSP90AB1POLBKDM4E
SCHEMBL1196115 0.84 HSP90AA1 (0.35) TSHRHSP90AA1HSP90AB1POLBKDM4E
SCHEMBL1196125 0.83 HSP90AA1 (0.36) TSHRHSP90AA1HSP90AB1ALDH1A1RAB9A
SCHEMBL1196079 0.82 TRPM8 (0.43) TSHRHSP90AA1HSP90AB1POLBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130131052-A1 Amelioration Of The Development Of Cataracts And Other Ophthalmic Diseases MATIER WILLIAM L (US) 2013-05-23 US disclosed
EP-1683783-B1 Chiral copper complex and production processes thereof and using the same SUMITOMO CHEMICAL CO (JP) 2012-03-14 EP disclosed
EP-1683782-B1 Chiral copper complex and production processes thereof and using the same SUMITOMO CHEMICAL CO (JP) 2012-03-14 EP disclosed
EP-1120402-B1 Chiral copper complex and production processes thereof and using the same SUMITOMO CHEMICAL CO (JP) 2008-06-25 EP disclosed
EP-1683782-A2 Chiral copper complex and production processes thereof and using the same Sumitomo Chemical Company, Limited (JP) 2006-07-26 EP disclosed
EP-1683783-A2 Chiral copper complex and production processes thereof and using the same Sumitomo Chemical Company, Limited (JP) 2006-07-26 EP disclosed
US-7009079-B2 Chiral copper complex and production processes thereof and using the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2006-03-07 US disclosed
US-20050090684-A1 Chiral copper complex and production processes thereof and using the same SUMITOMO CHEMICAL CO., LTD. 2005-04-28 US disclosed
US-6670500-B2 Chiral copper complex and production processes thereof and using the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2003-12-30 US disclosed
US-6469198-B2 OBTAINED BY CONTACTING N-SALICYLIDENEAMINOALCOHOL WITH MONO OR DIVALENT COPPER COMPOUND; FORMATION OF OPTICALLY ACTIVE CYCLOPROPANE-CARBOXYLIC ESTER FROM PROCHIRAL OLEFIN AND DIAZOACETIC ACID ESTER SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2002-10-22 US disclosed
US-20020004618-A1 Chiral copper complex and production processes thereof and using the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2002-01-10 US disclosed
US-20010037036-A1 Chiral copper complex catalyst composition and asymmetric production process using the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2001-11-01 US disclosed
EP-1120402-A2 Chiral copper complex and production processes thereof and using the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2001-08-01 EP disclosed
EP-1120401-A2 Chiral copper complex catalyst composition and asymmetric production process using the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2001-08-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050090684-A1 Chiral copper complex and production processes thereof and using the same SOD1, CYP1A1, NFXL1 TSHR 1375/4885HSP90AA1 2642/4885HSP90AB1 3158/4885
US-20010037036-A1 Chiral copper complex catalyst composition and asymmetric production process using the same AP1M1, UBA3, AP1S1 TSHR 4320/4885HSP90AA1 2888/4885HSP90AB1 3779/4885
US-20130131052-A1 Amelioration Of The Development Of Cataracts And Other Ophthalmic Diseases C3AR1, C1R, AKR1C3 TSHR 246/4885HSP90AA1 3348/4885HSP90AB1 3148/4885
US-20020004618-A1 Chiral copper complex and production processes thereof and using the same SOD1, XDH, NFXL1 TSHR 2499/4885HSP90AA1 2029/4885HSP90AB1 2576/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.